Cilengitide trifluoroacetate

For research use only.

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

28 publications

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 454 In stock
USD 270 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cilengitide trifluoroacetate has been cited by 28 publications

Purity & Quality Control

Choose Selective Integrin Inhibitors

Biological Activity

Description Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Targets
αvβ3 receptor [1]
(Cell-free assay)
αvβ5 receptor [2]
(Cell-free assay)
4.1 nM 79 nM
In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. [1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and fibrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. [2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. [3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. [4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LN-308  NX3nWpRCTnWwY4Tpc44hSXO|YYm= MVixM|ExNzFyMPMAje69dQ>? MUWyOEBp NGXsWlFFVVORwrC= M1i5O5Jm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MnnwNlY2ODByNU[=
ZH-161 MVTGeY5kfGmxbjDBd5NigQ>? NH3CR4UyNzFy4pEJ{txu MVyyOEBp MVfEUXNQyqB? NVfnUWV1emWmdXPld{BFWkVicnXwc5J1\XJiYXP0bZZqfHl? M{nGS|I3PTByMEW2
S-24 NI\ZToxHfW6ldHnvckBCe3OjeR?= MnnONU8yOOLCid88cS=> NEHMRXIzPCCq NWTwS2xsTE2VT9Mg MWDy[YR2[2W|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=> NF3vPJQzPjVyMEC1Oi=>
HaCaT  M3HXcGZ2dmO2aX;uJGF{e2G7 Ml7JNVDjiIoQvH2= MX20PEBp NXXLd2lDTE2VT9Mg NXH2S4J2emWmdXPld{BVT0ZvzsKyxsBuWk6DIHX4dJJme3Orb36= MlTONlY2ODByNU[=
LN-308  M4rCc2Z2dmO2aX;uJGF{e2G7 MYSxNQKBkc7:bR?= MXSyOEBp MX;EUXNQyqB? MnS5doVlfWOnczDBbHIheHKxdHXpckBt\X[nbIOgZY5lKESURTDy[ZBwenSncjDhZ5Rqfmm2eR?= MWiyOlUxODB3Nh?=
REN NF3IV49E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWSxJI5ONTJyMDFOwG0> NXGwSGVlPzJiaB?= M1Wyb4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX;uTYwzOjR3OUWyO|Q>
MSTO-211H M3;xXGNmdGxiVnnhZoltcXS7IFHzd4F6 NUPRSIFROSCwTT2yNFAh|ryP MnzYO|IhcA>? NE\kenBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnXNNlQ2QTV{N{S=
MM05 NFX6[nhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGWyWIcyKG6PLUKwNEDPxE1? NXe1eXo6PzJiaB?= NHTVT4hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIDwbnEzPDV7NUK3OC=>
H28 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF70eGgyKG6PLUKwNEDPxE1? M37pbVczKGh? MWXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NYXVOIJJOjR3OUWyO|Q>
SCC25 NX30SZd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Ke|YvOjYkgKOyNFDDqML3TR?= MlXPO|IhcA>? M3zFcpJme3WudIOgcY9l\XKjdHWsJIRwe2VvZHXw[Y5l\W62IHfyc5d1cCCrbnjpZol1cW:w NW\RNIhGOjR3NUewOVY>
CAL27 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPhO3g5Pi5{NfMAl|IxOMLiwsXN NGfjbYM4OiCq NIS0UVFz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?= M1mzc|I1PTV5MEW2
FaDu  NVLoOppQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\FZVYvOjYkgKOyNFDDqML3TR?= MX[3NkBp M161[ZJme3WudIOgcY9l\XKjdHWsJIRwe2VvZHXw[Y5l\W62IHfyc5d1cCCrbnjpZol1cW:w NVT5XoppOjR3NUewOVY>
SCC25 NFfsUHpCeG:ydH;zbZMhSXO|YYm= NEXXO5kzPcLiwsXNxsA> MmnUOFjDqGkEoB?= MX3pcoR2[2W|IHHwc5B1d3Orcx?= MlXVNlQ2PTdyNU[=
CAL27 MWrBdI9xfG:|aYOgRZN{[Xl? NH\IfW0zPcLiwsXNxsA> M1XY[FQ5yqCqwrC= NVvLNlhJcW6mdXPld{BieG:ydH;zbZM> NFLQfWczPDV3N{C1Oi=>
FaDu  M3jW[mFxd3C2b4Ppd{BCe3OjeR?= MoW4NlXDqML3TdMg MkTOOFjDqGkEoB?= NGG2N49qdmS3Y3XzJIFxd3C2b4Ppdy=> NETHRY4zPDV3N{C1Oi=>
T-47D NID1VFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPUXpExNTJyIN88US=> NFmwW446PiCq MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NX3KelA1OjRzNUOxNFI>
MCF-7  NVu2[XhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMVIxKM7:TR?= NWrRRYZPQTZiaB?= NYXPPYJPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3LSXVI1OTV|MUCy
T-47D NHvLVYNCeG:ydH;zbZMhSXO|YYm= M4\4TFAuOjBizszN MYO0PEBp MlTmbY5lfWOnczDhdI9xfG:|aYO= NETJUHozPDF3M{GwNi=>
MCF-7  MlXDRZBweHSxc3nzJGF{e2G7 MoLlNE0zOCEQvF2= NVLXb3hSPDhiaB?= MWPpcoR2[2W|IHHwc5B1d3Orcx?= NF;OXFczPDF3M{GwNi=>
U87MG NFPCPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\nSFAuOjVizszN MVOyOE81QCCq NWSwenRQcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NFvLPFgzOzN3NEiwOy=>
U251MG M3rqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TzflAuOjVizszN M17QS|I1NzR6IHi= NEPMd21qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Mon5NlM{PTR6MEe=
U87MG M1fM[mFxd3C2b4Ppd{BCe3OjeR?= MV:xJOK2VQ>? NWTKb4FTPDhiaB?= M2izWolv\HWlZYOgZZBweHSxc3nz MXGyN|M2PDhyNx?=
U251MG MV3BdI9xfG:|aYOgRZN{[Xl? MU[xJOK2VQ>? MoTuOFghcA>? Mn3hbY5lfWOnczDhdI9xfG:|aYO= MWGyN|M2PDhyNx?=
U251 NU\MVmluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G3VFAuOjVizsznM41N Mn:3NE01QCCq MnPMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NF;CSmgzOTd6OEO0Ny=>
U87  MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\QTZVOOC1{NTFOwIcwdUx? NInHbpExNTR6IHi= NH\RdZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NVvCN3NCOjF5OEizOFM>
U251 Mlf0RZBweHSxc3nzJGF{e2G7 M1u4T|I2KM7:Zz;tUC=> MXuyOE81QCCq M130Solv\HWlZYOgZZBweHSxc3nzJIF1KDR6IHigd4lodmmoaXPhcpRtgQ>? M2PJVlIyPzh6M{Sz
U87  MkXXRZBweHSxc3nzJGF{e2G7 M{L4fFI2KM7:Zz;tUC=> NHPEdGIzPC92ODDo M3vOdolv\HWlZYOgZZBweHSxc3nzJIF1KDR6IHigd4lodmmoaXPhcpRtgQ>? MlnuNlE4QDh|NEO=
U251 M1jWOmZ2dmO2aX;uJGF{e2G7 NInFXnIxNTJ3IN88[{9uVA>? NHLI[|AyOiCqwrC= M3juPIlv\HWlZYOgZZV1d3CqYXf5JIRwe2ViZHXw[Y5l\W62bIm= Ml7BNlE4QDh|NEO=
U87  MXnGeY5kfGmxbjDBd5NigQ>? NFfSdGUxNTJ3IN88[{9uVA>? MY[xNkBpyqB? MVjpcoR2[2W|IHH1eI9xcGGpeTDkc5NmKGSncHXu[IVvfGy7 M2fXNlIyPzh6M{Sz
U87MG MXzGeY5kfGmxbjDBd5NigQ>? NIj4[VExNjFxMT:xNEDPxE1? MofhNlQhcA>? MmPDbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M{\yUFE6OjJzMUex
LN-308 Ml\wSpVv[3Srb36gRZN{[Xl? MkPPNE4yNzFxMUCg{txO NU\rNXR3OjRiaB?= MXLpcZBicXK|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MoPRNVkzOjFzN{G=
LN-18 NFnOWI1HfW6ldHnvckBCe3OjeR?= NFf4UHcxNjFxMT:xNEDPxE1? NYjZcmFuOjRiaB?= M3XINolueGGrcoOgeIhmKGGmaHXzbY9vKG:oIHPlcIx{KHSxII\peJJwdmWldHnuJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NXfhXWR{OTl{MkGxO|E>
T98G M1;6ZmZ2dmO2aX;uJGF{e2G7 NYCwWZlnOC5zL{GvNVAh|ryP M333XlI1KGh? MojlbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3\lelE6OjJzMUex
LNT-229  NHzpb2pHfW6ldHnvckBCe3OjeR?= MXywMlEwOS9zMDFOwG0> M{fablI1KGh? Mmf0bY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mly2NVkzOjFzN{G=
HMEC-1  MkTXSpVv[3Srb36gRZN{[Xl? MnHtNU82NzVyIN88[{9udA>? MYOyOEBp NXnhUHJDcW6mdXPld{BiKGSxc3Wg[IVx\W6mZX70JIRmfGGlaH3lcpTDqA>? NXq3Z49KOTlzMUSwNFU>
HMEC-1  M4PzNHBzd2yrZnXyZZRqd25iQYPzZZk> NF7jVFcyNzVxNUCg{txoN22u MnHINlQwPDhxN{KgbC=> MkHybY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWOxPVEyPDByNR?=
HMEC-1  MWnBdI9xfG:|aYOgRZN{[Xl? M{DwXVEwPS93MDFOwIcwdWx? NH[5RnAzPCCq NID1WmhqdmS3Y3XzJIFxd3C2b4Ppdy=> M4O3cVE6OTF2MEC1
G28 M4HHV3Bzd2yrZnXyZZRqd25iQYPzZZk> MXOxM|UwPTBizsznM41t NV7BN|RGOjRxNEivO|IhcA>? Ml7DbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MmfpNVkyOTRyMEW=
G44 M{Gyd3Bzd2yrZnXyZZRqd25iQYPzZZk> MkLONU82NzVyIN88[{9udA>? M3m5TVI1NzR6L{eyJIg> MVPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NYfQbm9EOTlzMUSwNFU>
G28 M4\RemFxd3C2b4Ppd{BCe3OjeR?= NH;VdJUyNzVxNUCg{txoN22u NWe3fZQ1OjRiaB?= MorjbY5lfWOnczDhdI9xfG:|aYO= NHjDRY4yQTFzNECwOS=>
G44 Ml\YRZBweHSxc3nzJGF{e2G7 NV\mUHJXOS93L{WwJO69\y:vbB?= NYnQPFNUOjRiaB?= NV;N[5FHcW6mdXPld{BieG:ydH;zbZM> NXTzZ5QyOTlzMUSwNFU>
HMEC-1  M4DZT2Z2dmO2aX;uJGF{e2G7 MlPPNlAwPDBxNkCg{txoN22u NHvQe2dqdmirYnn0d{BHSUtiYX7kJHNz[8Li MoLvNVkyOTRyMEW=
G28 NIPrdnJHfW6ldHnvckBCe3OjeR?= NInhNG42OCEQvHevcYw> MlvRN|AwPjBxMUKwJI1qdg>? M1WzSolvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBHSUtuIGPyZ{BidmRiQXv0 M1\KblE6OTF2MEC1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFAK / p-AKT ; 

PubMed: 19114005     


G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt.

GLI1; 

PubMed: 31366904     


Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs. 

19114005 31366904
Immunofluorescence
VE-cadherin / β3 integrin ; 

PubMed: 19212436     


Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.

19212436
Growth inhibition assay
Cell number ; 

PubMed: 24153102     


Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.

24153102
In vivo Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). [5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. [6]

Protocol

Kinase Assay:[2]
- Collapse

Integrin-binding competition assay:

Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 10 μM MnCl2, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.
Cell Research:[3]
- Collapse
  • Cell lines: Human microvascular endothelial cell line HMEC-1
  • Concentrations: 1-50 μg/mL
  • Incubation Time: 3 days
  • Method: HMEC-1 (1×104 per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Human glioblastoma xenografts U87 MG
  • Dosages: 100μg
  • Administration: Daily i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (142.31 mM)
Water 8 mg/mL (11.38 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 702.68
Formula

C29H41F3N8O9

CAS No. 199807-35-7
Storage powder
in solvent
Synonyms EMD 121974, NSC 707544
Smiles CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01517776 Terminated Drug: Cilengitide|Drug: Temozolomide Gliomas Martin-Luther-Universität Halle-Wittenberg|Merck KGaA Darmstadt Germany January 2012 Phase 2
NCT01118676 Completed Drug: cilengitide radiochemotherapy Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Institut Claudius Regaud|Merck KGaA Darmstadt Germany March 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

  • Answer:

    S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

  • Question 2:

    Is Cilengitide a TFA salt?

  • Answer:

    S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Integrin Signaling Pathway Map

Tags: buy Cilengitide|Cilengitide ic50|Cilengitide price|Cilengitide cost|Cilengitide solubility dmso|Cilengitide purchase|Cilengitide manufacturer|Cilengitide research buy|Cilengitide order|Cilengitide mouse|Cilengitide chemical structure|Cilengitide mw|Cilengitide molecular weight|Cilengitide datasheet|Cilengitide supplier|Cilengitide in vitro|Cilengitide cell line|Cilengitide concentration|Cilengitide nmr|Cilengitide in vivo|Cilengitide clinical trial|Cilengitide inhibitor|Cilengitide Cytoskeletal Signaling inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID